Indaptus Therapeutics Inc (INDP)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeffrey A. Meckler
Employees:
5
12 HARTOM STREET, HAR HOTZVIM, JERUSALEM, ISRAEL 777512
97225864657

Indaptus Therapeutics, Inc. develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors.

Data derived from most recent annual or quarterly report
Market Cap 23.187 Million Shares Outstanding8.401 Million Avg 30-day Volume 21.55 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3
Price to Revenue0.0 Debt to Equity0.0 EBITDA-12.981 Million
Price to Book Value1.8575 Operating Margin0.0 Enterprise Value9.937 Million
Current Ratio2.337 EPS Growth0.828 Quick Ratio1.948
1 Yr BETA 0.3434 52-week High/Low 4.08 / 1.25 Profit Margin0.0
Operating Cash Flow Growth60.3602 Free Cash Flow to Firm (FCFF) TTM -6.869 Million Free Cash Flow to Equity (FCFE) TTM-6.675 Million
Altman Z-Score-16.8599
View SEC Filings from INDP instead.

View recent insider trading info

Indaptus Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding INDP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INDP

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-16 by ANDERSON GLEN R.
  • 4: filed on 2023-08-07 by WALTZMAN ROGER J.
  • 4: filed on 2023-05-30 by GILBERT MARK JOHN
  • 4: filed on 2023-02-14 by MARTELL ROBERT
  • 3: filed on 2023-02-14 by MARTELL ROBERT
  • 4: filed on 2023-01-20 by MECKLER JEFFREY A
  • 4: filed on 2023-01-20 by LINSCOTT WALT ADDISON
  • 4: filed on 2023-01-20 by SASSI NIR
  • 4: filed on 2023-01-20 by NEWMAN MICHAEL JAMES
  • 4: filed on 2022-11-22 by MECKLER JEFFREY A

    • Events (8k)

  • 8-K: filed on 2021-08-09:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 8.01: Other Events
  • 8-K: filed on 2021-07-29:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-07-23:
    Item 8.01: Other Events
  • 8-K: filed on 2021-07-16:
    Item 8.01: Other Events
  • 8-K: filed on 2021-06-22:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-04-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-03-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-12-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    103.4 Thousand total shares from 3 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ANDERSON GLEN R.

    • 10% Owner
    		 1,190,400 2023-08-10 1

    WALTZMAN ROGER J. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-08-07 2

    HAYES WILLIAM B

    • Director
    		 0 2023-05-25 1

    MADDALUNA ANTHONY J

    • Director
    		 0 2023-05-25 1

    POMERANTZ ROGER

    • Director
    		 0 2023-05-25 1

    KARAH HILA

    • Director
    		 0 2023-05-25 1

    GILBERT MARK JOHN

    • Director
    		 0 2023-05-25 1

    MARTELL ROBERT

    • Director
    		 0 2023-02-13 2

    MECKLER JEFFREY A CEO AND DIRECTOR

    • Officer
    • Director
    		 100,000 2023-01-18 2

    LINSCOTT WALT ADDISON CHIEF BUSINESS OFFICER

    • Officer
    		 40,000 2023-01-18 1

    SASSI NIR CHIEF FINANCIAL OFFICER

    • Officer
    		 40,000 2023-01-18 1

    NEWMAN MICHAEL JAMES CSO AND DIRECTOR

    • Officer
    • Director
    • 10% Owner
    		 43,250 2023-01-18 1

    O'CALLAGHAN BRIAN

    • Director
    		 13,750 2022-09-30 0

    LITCHEV BOYAN VESSELINOV CHIEF MEDICAL OFFICER

    • Officer
    		 90,000 2022-02-01 0

    LEE HOONMO

    • Director
    		 13,750 2021-08-04 0

    NAVON NADAV CHIEF OPERATING OFFICER

    • Officer
    		 0 2020-09-16 0

    KOZARICH JOHN W

    • Director
    		 0 2020-07-15 0

    GENDREAU R MICHAEL CHIEF MEDICAL OFFICER

    • Officer
    		 0 2020-02-17 0

    DEXCEL PHARMA TECHNOLOGIES LTD.

    OREN DAN

    • 10% Owner
    		 No longer subject to file 2020-01-31 0

    SILBERMAN ISSAC

    • Director
    		 4,000 2019-11-19 0

    BIANCO GIL

    • Director
    		 0 2019-06-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ANDERSON GLEN R. - > 10% Owner by anderson family trust u/a dtd 01/07/2018

    		2023-08-16 18:01:31 -0400 2023-08-14 P 23,934 $2.34 a 1,190,400 indirect 1.6736 6.6946 15.4812 65.272 23 -2.9289 7

    ANDERSON GLEN R. - > 10% Owner by anderson family trust u/a dtd 01/07/2018

    		2023-08-16 18:01:31 -0400 2023-08-11 P 35,064 $2.12 a 1,166,466 indirect 1.6736 6.6946 15.4812 65.272 23 -2.9289 7

    ANDERSON GLEN R. - > 10% Owner by anderson family trust u/a dtd 01/07/2018

    		2023-08-16 18:01:31 -0400 2023-08-10 P 44,354 $1.94 a 1,131,402 indirect 1.6736 6.6946 15.4812 65.272 23 -2.9289 7

    WALTZMAN ROGER J. - Officer CHIEF MEDICAL OFFICER

    		2023-08-07 17:25:41 -0400 2023-08-07 A 90,000 a 90,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 22:15:03 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 21:45:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 21:15:03 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 20:45:05 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 20:15:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 19:45:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 19:15:03 UTC 0.0 0.0 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 18:45:03 UTC 0.0 0.0 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 18:15:03 UTC 0.0 0.0 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 17:45:03 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 17:15:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 16:45:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 16:15:03 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 15:45:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 15:15:04 UTC -7.1217 12.4417 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 14:45:04 UTC -7.1342 12.4542 100000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 14:15:04 UTC -7.1342 12.4542 95000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 13:45:03 UTC -6.9032 12.2232 95000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 13:15:04 UTC -6.9032 12.2232 95000
    INDAPTUS THERAPEUTICS INC INDP 2023-09-29 12:45:05 UTC -6.9032 12.2232 95000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments